NANOVIRICIDES, INC.

NNVCSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1379006

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$5.4M	$6.4M	$5.8M	$6.1M	$5.9M
Operating Expenses	$8.5M	$8.9M	$8.1M	$8.7M	$8.7M
Operating Income (Loss)	-$8.5M	-$8.9M	-$8.1M	-$8.7M	-$8.7M
Interest Expense	—	—	$5.1K	$85.4K	$0.00
Nonoperating Income (Expense)	$222.0K	$354.9K	$6.7K	-$78.1K	$235.2K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	-$8.8M	-$8.4M
Income Tax Expense (Benefit)	—	—	—	—	$0.00
Net Income (Loss) Attributable to Parent	-$8.3M	-$8.6M	-$8.1M	-$8.8M	-$8.4M
Earnings Per Share, Basic	-$0.70	-$0.74	-$0.70	-$0.81	—
Earnings Per Share, Diluted	-$0.70	-$0.74	-$0.70	-$0.81	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$12.8M	$16.9M	$23.5M	$30.3M	$23.9M
Assets, Current	$5.0M	$8.4M	$14.4M	$20.8M	$14.0M
Cash and Cash Equivalents, at Carrying Value	$4.8M	$8.1M	$14.1M	$20.5M	$13.7M
Liabilities	$1.3M	$2.0M	$412.8K	—	—
Liabilities, Current	$1.4M	$534.3K	$412.8K	$351.1K	$2.2M
Long-term Debt, Excluding Current Maturities	—	—	—	—	—
Stockholders' Equity Attributable to Parent	$14.9M	$23.1M	$29.9M	$21.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$6.3M	-$5.7M	-$5.9M	-$8.2M	-$6.8M
Net Cash Provided by (Used in) Investing Activities	-$156.6K	-$151.7K	-$324.3K	—	—
Net Cash Provided by (Used in) Financing Activities	$3.1M	-$94.8K	-$234.7K	$15.3M	$2.4M
Payments to Acquire Property, Plant, and Equipment	$156.6K	$151.7K	$324.3K	$238.8K	$73.8K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)